AbbVie outdoes rumored J&J bid with $21bn Pharmacyclics buy
This article was originally published in Scrip
AbbVie swooped in to buy Pharmacyclics for $21bn on 4 March after several days of speculation that the Sunnyvale, California-based biopharmaceutical firm would be acquired by its Imbruvica (ibrutinib) development partner Johnson & Johnson for as much as $19bn.
You may also be interested in...
Deal Snapshot: Akeso has already sought to secure FDA approval for its PD-1 inhibitor, but the agency has shown reluctance to approve drugs based on China-only data.
AbbVie/Pharmacyclics executives Danelle James and Mohamed Zaki, in an interview at ASH, discussed Imbruvica's worth in chemo-free settings and noted additional value that could be created with shorter durations of treatment in combination regimens.
Analysts generally were not surprised that Imbruvica plus R-CHOP did not provide a significant benefit versus R-CHOP alone in a hard-to-treat type of non-Hodgkin lymphoma. The failure leaves an opening for competitors, such as Celgene's Revlimid, which will soon have data in this indication.